GlassScriptPhysician profile
Susan Blue
NPI 1578540431
$15,017.66
in general payments reported to CMS, 2019-2025
43 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,977 · 2020: $1,620 · 2021: $1,366 · 2022: $1,327 · 2023: $1,471 · 2024: $258.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,728.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,728.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $9,445.84 | 2019-2024 | Mavenclad, Mavenclad |
| Biogen, INC. | $594.76 | 2019-2023 | Avonex, Vumerity |
| Teva Pharmaceuticals USA, INC. | $532.85 | 2019-2023 | Ajovy |
| Abbvie INC. | $466.37 | 2019-2023 | Ubrelvy, Qulipta |
| Novartis Pharmaceuticals Corporation | $430.57 | 2019-2023 | |
| Genzyme Corporation | $352.06 | 2019-2022 | |
| Lilly USA, LLC | $269.79 | 2019-2022 | |
| Amgen INC. | $226.20 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $210.42 | 2023 | Aptiom |
| Ucb, INC. | $195.16 | 2019-2022 | |
| Amneal Pharmaceuticals LLC | $183.80 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $174.06 | 2021 | |
| Celgene Corporation | $160.83 | 2021-2022 | |
| Grifols USA, LLC | $153.00 | 2019 | |
| Supernus Pharmaceuticals, INC. | $131.55 | 2019-2023 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Blue listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.